- Home
- EVG vs ENTA Comparison
EVG vs ENTA Comparison
Compare EVG & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVG
- ENTA
- Stock Information
- Founded
- EVG 2005
- ENTA 1995
- Country
- EVG United States
- ENTA United States
- Employees
- EVG N/A
- ENTA N/A
- Industry
- EVG Investment Managers
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- EVG Finance
- ENTA Health Care
- Exchange
- EVG Nasdaq
- ENTA Nasdaq
- Market Cap
- EVG 144.8M
- ENTA 154.0M
- IPO Year
- EVG N/A
- ENTA 2013
- Fundamental
- Price
- EVG $10.95
- ENTA $5.27
- Analyst Decision
- EVG
- ENTA Buy
- Analyst Count
- EVG 0
- ENTA 4
- Target Price
- EVG N/A
- ENTA $17.25
- AVG Volume (30 Days)
- EVG 49.4K
- ENTA 194.0K
- Earning Date
- EVG 01-01-0001
- ENTA 05-20-2025
- Dividend Yield
- EVG 8.68%
- ENTA N/A
- EPS Growth
- EVG N/A
- ENTA N/A
- EPS
- EVG N/A
- ENTA N/A
- Revenue
- EVG N/A
- ENTA $66,590,999.00
- Revenue This Year
- EVG N/A
- ENTA N/A
- Revenue Next Year
- EVG N/A
- ENTA N/A
- P/E Ratio
- EVG N/A
- ENTA N/A
- Revenue Growth
- EVG N/A
- ENTA N/A
- 52 Week Low
- EVG $9.13
- ENTA $4.09
- 52 Week High
- EVG $10.86
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- EVG 55.12
- ENTA 45.38
- Support Level
- EVG $10.80
- ENTA $4.96
- Resistance Level
- EVG $10.99
- ENTA $6.23
- Average True Range (ATR)
- EVG 0.19
- ENTA 0.33
- MACD
- EVG 0.03
- ENTA -0.01
- Stochastic Oscillator
- EVG 82.14
- ENTA 24.41
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.